Last edition
News about "Cardiometabolic Diseases"
TUL Signs Exclusive License Deal with Novo Nordisk for UBT251
Under the license agreement, Novo Nordisk will obtain exclusive worldwide rights (excluding Chinese mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize UBT251.
Cardiometabolic Diseases | 25/03/2025 | By Aishwarya
Valo Health and Novo Nordisk to Develop Novel Treatments for Cardiometabolic Diseases
The expanded collaboration will continue to leverage the capabilities of Valo’s Opal Computational Platform, as well as key joint capabilities in human data and genetics with Novo Nordisk’s expertise in cardiometabolic diseases.
Cardiometabolic Diseases | 09/01/2025 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy